Document is current
Any future updates will be listed below
-
Authors
Moutschen, Michel https://orcid.org/0000-0002-6405-1785
Boulanger, Cécile https://orcid.org/0000-0002-2969-6131
Dehoorne, Joke https://orcid.org/0000-0003-4759-0717
Joos, Rik https://orcid.org/0000-0002-6087-3861
Roufosse, Florence https://orcid.org/0000-0002-5288-0375
Sabato, Vito https://orcid.org/0000-0002-1321-314X
van der Hilst, Jeroen https://orcid.org/0000-0003-4527-6310
Maury, Eleonore https://orcid.org/0000-0001-7517-1988
Rabijns, Hilde https://orcid.org/0009-0007-5504-3293
Witterzeel, Marijn
Wouters, Carine https://orcid.org/0000-0002-6426-8845
- License Information
-
More Information
Article History
Received: 7 February 2025
Accepted: 16 May 2025
First Online: 29 May 2025
Declarations
:
: This study was conducted in accordance with the principles of the Declaration of Helsinki. The study was approved by the Ethics Committee of the University Hospital Sart-Tilman of Liège (local study number: 2019/119) and by the local Ethics Committees of the participating sites. All patients provided written informed consent (or parent’s/legally authorized representative(s) in case of pediatric patient), prior to any study-related procedure.
: Not applicable.
: FR has received consultancy and/or speaker fees from GlaxoSmithKline, AstraZeneca, Menarini, and Merck. VS has participated in advisory boards for Novartis. JvdH has received financial compensation as an unrestricted educational grant and/or financial compensation for advisory boards and/or speaker fees from Novartis, Sobi, GlaxoSmithKline, Valneva, Gilead, Takeda, and BMS. EM, HR, and MW are employees of Novartis. HR was an employee of Novartis at the time of the study and manuscript preparation; but is no longer so at the time of publication. CW has received consultancy and/or advisory board fees from Sobi, Novartis, and UCB; speaker fees from Novartis; and preceptorship support from Novartis. MM, CB, JD, and RJ declare no conflict of interest.
